Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a setback on the early-stage BCX10013 study.
The company noted recent dose-related observations in an ongoing BCX10013 nonclinical study would delay the clinical program.
BioCryst planned to advance BCX10013 into patient studies in mid-2023, including in patients with paroxysmal nocturnal hemoglobinuria (PNH), to evaluate once-daily dosing.
In January, the company announced initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers.
It showed rapid, sustained, and >97 percent suppression of the complement system’s alternative pathway (AP) 24 hours following a single 110 mg dose and that BCX10013 has been safe and generally well-tolerated at all doses studied to date.
Needham writes that they believe the sell-off was overdone and that BCRX’s 25% YTD decline brought its shares to the level that fails to adequately capture Orladeyo’s sales (2023 sales guidance of ≥$320 million, +27%Y/Y) and growth trajectory.
The analyst upgraded the stock to Buy from Hold with a price target of $14.
The analyst expects Orladeyo can attain peak sales of $700 million, given that competition from another oral HAE prophylactic is unlikely for at least 5-7 years.
BCRX’s OpEx spending is high, but the company is well-funded, with a cash balance of $443.9 million. The BCX10013 setback may prompt R&D spending cuts that accelerate the progression to break even, potentially as early as 2024.
Price Action: BCRX shares are up 12.33% at $9.70 on the last check Wednesday.
Latest Ratings for BCRX
Date | Firm | Action | From | To |
|---|---|---|---|---|
Dec 2021 | Oppenheimer | Initiates Coverage On | Outperform | |
Nov 2021 | RBC Capital | Maintains | Sector Perform | |
Nov 2021 | Barclays | Maintains | Overweight |
View More Analyst Ratings for BCRX
View the Latest Analyst Ratings
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Analyst Sees Attractive Entry Opportunity After BioCryst’s Pipeline Setback originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Source: https://finance.yahoo.com/news/analyst-sees-attractive-entry-opportunity-193122895.html